Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabio Zattoni

Showing results (1-10 of 180) with videos related to

Pageof 18
Sort By:
Urologic Oncology|December 30, 2014
Income inequality and treatment of African American men with high-risk prostate cancerFabio Zattoni
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 18, 2018
THE WAR IS OPENED: PSMA VS. <sup>64</sup>CuCL<sub>2</sub> VS. CHOLINE PET/CTLaura Evangelista, Fabio Zattoni
World Journal of Urology|February 9, 2018
Preoperative chronic kidney disease before radical cystectomy as predictor of oncological outcomes: a pick of the iceberg?Fabio Zattoni, Alessandro Morlacco, Filiberto Zattoni
European Urology Oncology|December 15, 2024
Re: Evelien J.E. van Altena, Bernard H.E. Jansen, Marieke L. Korbee, et al. Prostate-specific Membrane Antigen Positron Emission Tomography Before Reaching the Phoenix Criteria for Biochemical Recurrence of Prostate Cancer After Radiotherapy: Earlier Detection of Recurrences. Eur Urol Oncol. 2025;8:417-424Giuseppe Reitano, Filippo Carletti, Fabio Zattoni
European Journal of Nuclear Medicine and Molecular Imaging|April 24, 2016
Can (68)GA-PSMA or radiolabeled choline PET/CT guide salvage lymph node dissection in recurrent prostate cancer?Fabio Zattoni, Andrea Guttilla, Laura Evangelista
European Urology|September 5, 2016
Re: Marlon Perera, Nathan Papa, Daniel Christidis, et al. Sensitivity, Specificity, and Predictors of Positive <sup>68</sup>Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol 2016;70:926-37Fabio Zattoni, Filiberto Zattoni, Laura Evangelista
Current Opinion in Urology|August 21, 2023
Optimal combination therapy for metastatic hormone-sensitive prostate cancer: new evidence, challenges and unanswered questionsFabio Zattoni, Pawel Rajwa, Giorgio Gandaglia, et al.
Annals of Translational Medicine|October 3, 2019
<sup>68</sup>Ga-dotatoc <i>vs.</i> <sup>18</sup>F-FDG <i>vs.</i> radiolabelled PSMA PET/CT in renal cancer patientsLaura Evangelista, Fabio Zattoni, Pierpaolo Alongi
Urologia|March 19, 2017
Risk stratification for benign prostatic hyperplasiaFabio Zattoni, Vincenzo Ficarra, Giacomo Novara
European Journal of Nuclear Medicine and Molecular Imaging|December 3, 2015
Radiolabelled choline and FDG PET/CT: two alternatives for the assessment of lymph node metastases in patients with upper urinary tract urothelial carcinomaFabio Zattoni, Laura Evangelista, Andrea Guttilla, et al.
Pageof 18

Showing results (1-10 of 180) with videos related to

Sort By:
Pageof 18
Urologic Oncology|December 30, 2014
Income inequality and treatment of African American men with high-risk prostate cancerFabio Zattoni
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 18, 2018
THE WAR IS OPENED: PSMA VS. <sup>64</sup>CuCL<sub>2</sub> VS. CHOLINE PET/CTLaura Evangelista, Fabio Zattoni
World Journal of Urology|February 9, 2018
Preoperative chronic kidney disease before radical cystectomy as predictor of oncological outcomes: a pick of the iceberg?Fabio Zattoni, Alessandro Morlacco, Filiberto Zattoni
European Urology Oncology|December 15, 2024
Re: Evelien J.E. van Altena, Bernard H.E. Jansen, Marieke L. Korbee, et al. Prostate-specific Membrane Antigen Positron Emission Tomography Before Reaching the Phoenix Criteria for Biochemical Recurrence of Prostate Cancer After Radiotherapy: Earlier Detection of Recurrences. Eur Urol Oncol. 2025;8:417-424Giuseppe Reitano, Filippo Carletti, Fabio Zattoni
European Journal of Nuclear Medicine and Molecular Imaging|April 24, 2016
Can (68)GA-PSMA or radiolabeled choline PET/CT guide salvage lymph node dissection in recurrent prostate cancer?Fabio Zattoni, Andrea Guttilla, Laura Evangelista
European Urology|September 5, 2016
Re: Marlon Perera, Nathan Papa, Daniel Christidis, et al. Sensitivity, Specificity, and Predictors of Positive <sup>68</sup>Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol 2016;70:926-37Fabio Zattoni, Filiberto Zattoni, Laura Evangelista
Current Opinion in Urology|August 21, 2023
Optimal combination therapy for metastatic hormone-sensitive prostate cancer: new evidence, challenges and unanswered questionsFabio Zattoni, Pawel Rajwa, Giorgio Gandaglia, et al.
Annals of Translational Medicine|October 3, 2019
<sup>68</sup>Ga-dotatoc <i>vs.</i> <sup>18</sup>F-FDG <i>vs.</i> radiolabelled PSMA PET/CT in renal cancer patientsLaura Evangelista, Fabio Zattoni, Pierpaolo Alongi
Urologia|March 19, 2017
Risk stratification for benign prostatic hyperplasiaFabio Zattoni, Vincenzo Ficarra, Giacomo Novara
European Journal of Nuclear Medicine and Molecular Imaging|December 3, 2015
Radiolabelled choline and FDG PET/CT: two alternatives for the assessment of lymph node metastases in patients with upper urinary tract urothelial carcinomaFabio Zattoni, Laura Evangelista, Andrea Guttilla, et al.
Pageof 18